From randomized clinical trials to real life data. An Italian clinical experience with ixekizumab and its management.

Interleukin(IL)-17 inhibitors display higher efficacy than both TNFi and IL-12/23i, which increased the goal psoriasis area severity index (PASI) from 75 to PASI 90 or even PASI 100. Ixekizumab, a recombinant, humanized IgG4 monoclonal antibody targeting IL-17A displayed a high efficacy and safety i...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Dermatol Ther
Hlavní autoři: Damiani, Giovanni, Conic, Rosalynn RZ, Pigatto, Paolo DM, Bragazzi, Nicola L, Pacifico, Alessia, Malagoli, Piergiorgio
Médium: Artigo
Jazyk:Inglês
Vydáno: 2019
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6579640/
https://ncbi.nlm.nih.gov/pubmed/30942952
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dth.12886
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky